Petros Grivas: Jonathan Chou’s amazing talk on bladder cancer surface biomarkers

Petros Grivas shared a post on X by Omar Mian, adding:

“Fantastic to see Jonathan Chou and hear his amazing talk on bladder cancer surface biomarkers! Huge opportunities for translational applications! Thanks, Hsieh Lab for organising.”

Quoting Omar Mian’s post:

“Great to see Jonathan Chou and hear about the amazing work he’s doing!”

Sources: Petros Grivas/X and Omar Mian/X

More posts featuring Petros Grivas.

Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance.

He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Omar Mian is a cancer researcher and radiation oncologist at the Fred Hutchinson Cancer Center and the University of Washington Radiation Oncology. Previously, Dr. Mian was a radiation oncologist and physician-scientist at Cleveland Clinic’s Lerner Research Institute.

His research focuses on the genetic and epigenetic mechanisms driving aggressive cancers of the genitourinary tract, with the aim of developing new therapeutic approaches.

Jonathan Chou is an Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF).

He treats advanced genitourinary cancers like prostate, bladder, kidney, and testicular cancers. Jonathan leads a research group focused on cancer metastasis, tumor microenvironment, therapeutic resistance, and developing CRISPR-based treatments for these malignancies.